Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Date:10/29/2008

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter financial results after the market closes on Thursday, November 6, 2008.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a clinical program update on Thursday, November 6, 2008 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 866-816-1982 (domestic) or 816-581-1712 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
7. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Abstract , ... in the biological sciences. In drug discovery research, immunoassays ... culture supernatants of treated cells. However, scientists often avoid ... cumbersome manipulations. Applied Biosystems has developed a singlestep, mix-and-read ...
... Purpose , ... of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) ... of assessing inter-individual and intra-individual metabolism variability. To be of ... to monitor these drugs is fast and easy to perform, ...
... Purpose , ... plays an important role in a number of functions, including the ... characterized by impaired, reduced or total absence of peroxisomes in cells, ... and hexacosanoic acids, in plasma. Some variants of these disorders are ...
Cached Biology Technology:Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 2Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 3Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 4Mix-and-Read, Bead- and Cell-Based Immunoassays Using the FMAT 8100 HTS System 5A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 2A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 3A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors) 4A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 2A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 3A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 4
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... University (Canada) have teamed up with genome researchers from ... bone samples from Siberia. The project also involved ... and researchers from Russia, the United Kingdom, France, and ... sequences from a woolly mammoth will be published on ...
... the first solid evidence that still "sharp" older brains store ... discovery is reported by a Johns Hopkins team in the ... prove to apply as well to human brains, it could ... therapies based on what healthy older brains are doing, rather ...
... Unscripted biochemical variations, or noise, leads to oscillations in ... have debated for decades the relative importance of nature ... behaves, and now UCSD scientists report that noise could ... , In a paper in Proceedings of the National ...
Cached Biology News:Scientists sequence DNA of woolly mammoth 2'Sharp' older brains are not the same as younger brains 2Phenotype is influenced by nature, nurture and noise 2
... Protein DetectorTM Microarray Dot Blot Kits overcome ... and quantitation over a wide range in ... ) detection. They are ideal for ... hundreds of samples for the presence of ...
AC input: 50-60 Hz 115-120 V...
... AP Conjugate Stabilizer is an aqueous ... protein and other non-toxic stabilizing chemicals ... pH 5.5 6.5. This ... methylisothiazolone and 0.02% bromonitrodioxane as a ...
... to Lambda Free Light Chain ... chains of human immunoglobulin. ... expressed epitope of lambda chain. Reacts ... free lambda chains but not with ...
Biology Products: